A Yale University study has found ibalizumab reduced viral replication and increased the count of immune cells in HIV patients, raising hopes for a new form of treatment for the disease.
GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping closer to potentially changing lives of patients living with
ViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination cutting the number of drugs taken to suppress the disease from three to two, f
Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment.
French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.